Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
leflunomide aryl hydrocarbon receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Disease Progression[MeSHID:D018450]
Physical Examination[MeSHID:D010808]
Rheumatoid Arthritis[MeSHID:D001172]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Multiple Sclerosis[MeSHID:D009103]
Disease[MeSHID:D004194]		 NA approved,investigational agonist
leflunomide aryl hydrocarbon receptor small molecule NA drugbank Disease Management[MeSHID:D019468]
Disease Progression[MeSHID:D018450]
Physical Examination[MeSHID:D010808]
Rheumatoid Arthritis[MeSHID:D001172]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]
Arthritis[MeSHID:D001168]		 NA approved,investigational agonist
leflunomide dihydroorotate dehydrogenase (quinone), mitochondrial small molecule NA drugbank , DGIDB Disease Management[MeSHID:D019468]
Disease Progression[MeSHID:D018450]
Physical Examination[MeSHID:D010808]
Rheumatoid Arthritis[MeSHID:D001172]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]
Arthritis[MeSHID:D001168]		 25.2 approved,investigational inhibitor
leflunomide dihydroorotate dehydrogenase (quinone), mitochondrial small molecule NA drugbank , DGIDB Disease Management[MeSHID:D019468]
Disease Progression[MeSHID:D018450]
Physical Examination[MeSHID:D010808]
Rheumatoid Arthritis[MeSHID:D001172]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Multiple Sclerosis[MeSHID:D009103]
Disease[MeSHID:D004194]		 25.2 approved,investigational inhibitor
leflunomide protein-tyrosine kinase 2-beta small molecule NA drugbank Disease Management[MeSHID:D019468]
Disease Progression[MeSHID:D018450]
Physical Examination[MeSHID:D010808]
Rheumatoid Arthritis[MeSHID:D001172]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Sclerosis[MeSHID:D009103]
Arthritis[MeSHID:D001168]		 NA approved,investigational antagonist
leflunomide protein-tyrosine kinase 2-beta small molecule NA drugbank Disease Management[MeSHID:D019468]
Disease Progression[MeSHID:D018450]
Physical Examination[MeSHID:D010808]
Rheumatoid Arthritis[MeSHID:D001172]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Multiple Sclerosis[MeSHID:D009103]
Disease[MeSHID:D004194]		 NA approved,investigational antagonist
click here to return to the previous page